Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
June 26, 2024 07:00 ET | Lyell Immunopharma, Inc
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
May 07, 2024 16:05 ET | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
May 06, 2024 08:00 ET | Lyell Immunopharma, Inc
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
March 05, 2024 16:30 ET | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
February 28, 2024 16:05 ET | Lyell Immunopharma, Inc
On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024Received Orphan Drug Designation for LYL845 for the treatment of melanomaExpect to...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Announces Participation in March Investor Conferences
February 26, 2024 16:05 ET | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
November 09, 2023 16:05 ET | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...